Atherosclerosis is associated with endothelial dysfunction and a heightened state of inflammation characterized, in part, by an increase in vascular myeloperoxidase and proteins modified by its principal oxidant, hypochlorous acid (HOCl). Here we examined whether probucol could protect against endothelial dysfunction induced by t h e t w o -e l e c t r o n o x i d a n t HOCl. Hypochlorous acid eliminated endotheliumdependent relaxation of rabbit aorta, whereas endothelial function and tissue cGMP was preserved and elevated, respectively, in animals pretreated with probucol. Exogenously added probucol also protected a g a i n s t HOCl-induced endothelial dysfunction.
In vitro, HOCl oxidized probucol in a two-phase process with rate constants k 1 = 2.7 ± 0.3 x 10 2 and k 2 = 0.7 ± 0.2 x 10 2 M -1 s -1 that resulted in a dose-and timedependent accumulation of probucol-derived disulfoxide, 4,4'-dithiobis(2,6-di-tert-butylphenol) (DTBP), DTBP-derived thiosulfonate, disulfone and sulfonic acid, together with 3,3',5,5'-tetra-tert-butyl-4,4'-diphenoquinone (DPQ) as determined by HPLC and mass spectrometry. Like HOCl, selected oneelectron oxidants converted probucol into DTBP and DPQ. Also, dietary and in vitro added DTBP protected aortic rings from HOCl-induced endothelial dysfunction and in vitro oxidation by HOCl gave rise to the thiosulfonate, disulfone and sulfonic acid intermediates and DPQ. However, the product profiles of the in vitro oxidation systems were different from those in aortas of rabbits receiving dietary probucol or DTBP ± HOCl-treatment. Together, the results show that both probucol and DTBP react with HOCl and protect against HOCl-induced endothelial dysfunction, although direct scavenging of HOCl is unlikely to be responsible for the vascular protection by the two compounds.
Atherosclerosis and its associated pathological conditions are characterized by abnormal
• NO bioactivity, such that vasodilatation in response to agonists for endothelium-derived
• NO release such as acetylcholine is impaired or replaced by constriction (1) . Endothelial dysfunction has been directly demonstrated in atherosclerotic human coronary arteries (1) and there is strong evidence that its presence predicts the occurrence of clinical events in patients with atherosclerosis (2) .
Oxidative events are thought to play an important role in endothelial dysfunction. For example, in animal models of atherosclerosis and hypercholesterolemia, vascular production of superoxide anion radical is increased (3) and this abnormality can decrease • NO bioactivity via formation of peroxynitrite (4) that itself can inactivate endothelial nitric oxide synthase (5) . Later stages of atherosclerosis, however, are more complex, and reactive species other than superoxide anion radical likely contribute to endothelial dysfunction (6) . In this context, myeloperoxidase is of particular interest, as it is present and active in human atherosclerotic lesions (7) , often associates closely with endothelial cells (8, 9) , and can catalytically consume • NO (10, 11) .
In addition, hypochlorous acid (HOCl), the major product of myeloperoxidase under physiologic conditions, may contribute to endothelial dysfunction in atherosclerosis (12) . There is evidence that HOCl-mediated oxidation occurs within and outside endothelial cells of human a t h e r o s c l e r o t i c l e s i o n s , b a s e d o n immunostaining with a monoclonal antibody specific for HOCl-modified proteins (13) . Also, HOCl-modified LDL, present in human lesions (13) , can inhibit • NO production by endothelial cells (14) , and HOCl-mediated chlorination of Larginine can produce a similar defect in endothelial cells by decreasing the stability of endothelial nitric oxide synthase (16) .
At present, little is known on how different antioxidants impact on HOCl-induced endothelial dysfunction.
Among the antioxidants relevant to cardiovascular disease, probucol is of particular interest, as it inhibits atherosclerosis in hypercholesterolemic rabbits (17, 18) , non-human primates (19) and humans (20) , and it prevents coronary heart disease and death in scavenger receptor class B type I/apolipoprotein E-deficient mice (21) . Probucol also reverses established plaques in rabbits (22) and xanthomas in humans (23) , and it effectively inhibits intimal thickening and restenosis in rabbits (24) , pigs (25) and humans (26) . Interestingly, probucol preserves endothelial function in cholesterol-fed rabbits (27) and, when given in conjunction with a lipid-lowering drug, also improves endothelium-dependent vasodilation in humans with coronary artery disease (28) , although the underlying mechanisms for this protective activity remain unclear. The aim of the present study therefore was to examine whether probucol protects against HOCl-induced endothelial dysfunction.
Materials and Methods

Materials-Probucol was obtained from
Jucker Pharma (Stockholm, Sweden), and 3,3',5,5'-tetra-tert-butyl-4,4'-bisphenol (BP), 4,4'-dithiobis(2,6-di-tert-butyl-phenol) (DTBP) a n d ( 2 , 2 '-azobis(2-amidino-propane)-hydrochloride (AAPH) from Polysciences (Warrington, PA). Authentic DPQ was prepared from BP (29) and purified by gradient reversedphase HPLC (see below). Acetylcholine, lead dioxide and ceric ammonium nitrate (purity 98%, a source of Ce 4+ ) were obtained from Sigma. 'Dulbecco's' phosphate buffered saline (DPBS, Sigma) was prepared from nanopure water and stored over Chelex-100 ® (BioRad, Richmond, CA) at 4 °C for 24 h to remove contaminating transition metals. All other reagents were of the highest quality available. Buffers were routinely filtered, argon-flushed and stored at 4 °C prior to use. Solutions of HOCl were prepared freshly before use by diluting reagent HOCl (Aldrich) into phosphate buffer (250 mM, pH 7.0) and standardizing with ε 235 nm ~ 100 M -1 cm -1 (hypochlorous acid) and ε 290 nm ~ 300 M -1 cm -1 (hypochlorite) (30) .
Animals-New Zealand White rabbits (2.5-3 kg) were obtained from a commercial farm (Wauchope, NSW Australia) and housed individually for the entire study period. Rabbits received normal chow (control) or chow supplemented with probucol (1%, w/w), DTBP (0.2%) or BP (0.02%) as described previously (31) ; these concentrations resulted in comparable drug levels in the aortas of supplemented animals. Feed and water were provided ad libitum for a period of 4 weeks judged to be sufficient time for circulating drug levels to reach a maximum (data not shown). Animals were weighed weekly; mean body weights did not differ between treatment groups. The local ethics committee approved the study.
Vascular reactivity-Perfused rabbit aortas were harvested and vascular reactivity studies performed as described (31) . Briefly, within 2 h of isolation, ring segments ~5 mm in length were mounted in a myobath system (World Precision Instruments, Sarasota, FL) containing 20 mL of Krebs solution aerated at 37 ºC with 5% CO 2(g) , and the dilatory response of half maximally norepinephrine pre-constricted rings to incremental doses of acetylcholine (10 -9 -10 -5 mol/L) determined. Where indicated, reagent HOCl (final concentration 400 µM) was added to the Krebs solution and the rings incubated for 5 min prior to thorough washing, preconstriction and assessment of vessel relaxation. In some studies rings were incubated with probucol or DTBP for 10 min, washed thoroughly and then exposed to HOCl prior to assessing endothelium-dependent relaxation. A maximum of three consecutive sequences of constriction/relaxation were performed for each ring.
Preparation of aortic homogenates-Aortic rings used in the vascular function studies were removed and immediately cut into small pieces, frozen in liquid nitrogen, and then pulverized and homogenized as described (32, 33 ). An aliquot (50 µL) of homogenate was removed for protein determination (BCA assay, Sigma) and the remainder extracted into methanol/hexane (5:1, v/v) (33), the resulting hexane fraction dried and the residue suspended in isopropanol for analysis of probucol and its oxidation products. For cGMP determinations, aortic segments were treated with vehicle (control) or HOCl (400 µ M) before addition of 1 µ M acetylcholine in the presence of 200 µM 3-isobutyl-1-methylxanthine and measurement of cGMP in the homogenate using a kit (Cayman Chemical, Ann Arbor, MI).
Probucol oxidation studies-Probucol is a highly lipophilic compound (partition coefficient between octanol and water = 10 versus 10.8 for octanol) (34) that readily distributes into lipoproteins. To mimic the biological situation, oxidation reactions were therefore performed with probucol (or DTBP) dissolved in hexane (2 mL) to which aliquots of HOCl were added to give the final concentrations indicated. The heterogeneous mixtures were shaken vigorously at 37 °C for 60 min, then placed on ice after adding 1 mL water, the hexane phase removed, dried under vacuum and resuspended in isopropanol (200 µL) for HPLC analyses. The aqueous phase was analyzed for the content of sulfate anion (SO 4 2- ) by ion exchange chromatography.
Analytical analyses-Probucol, DTBP, BP and DPQ were analyzed by gradient reversedphase HPLC (33, 35) and quantified by peak area comparison with authentic standards. Under the conditions used, BP, DTBP, probucol and DPQ eluted at 12.5, 19.2, 20.8 and 28.4 min, respectively. Other oxidation products resolved by this HPLC system were also quantified by peak area comparison, using analytically pure samples obtained from semi-preparative (LC-18, 20 mm x 25 cm, 5 µm) fractionation of the reaction mixture. Isolated samples were dried under vacuum, re-dissolved to a known concentration and assessed for purity by analytical HPLC (LC-18, 4.6 mm x 25 cm, 5 µm) in combination with mass spectrometry (see below).
The accumulation of DPQ was monitored at 420 nm, while all other products were monitored at 270 nm. Where required, 1 H-NMR (Bruker 600 MHz NMR spectrometer fitted with a standard hydrogen probe) was performed using authentic samples of DTBP and analytically pure DTBP isolated by HPLC after oxidation of probucol with HOCl.
Ion exchange chromatography was performed on a Waters IC PAK-A column (4.6 x 50 mm x 10 µ m) with an eluent containing sodium gluconate (0.32 g/L), boric acid (0.36 g/L), sodium tetraborate decahydrate (0.5 g/L), glycerol (5.0 mL/L), n-butanol (20 mL/L) and acetonitrile (120 mL/L) at a flow rate of 1.0 mL/min. Eluting anions were detected with a refractive index detector (limit of detection 10 µM), with sulfate anion eluting at ~18 min identified by comparison with an authentic standard.
Mass spectrometry-Product masses were determined using electrospray ionization mass spectrometry (ESI-MS). Spectra were acquired using an API QStar Pulsar i hybrid tandem mass spectrometer (Applied Biosystems, Foster City CA). Samples (~10 pmol, 1 µL) were dissolved in water/acetonitrile (1:4, v/v), loaded into nanospray needles (Proxeon, Denmark) and the tip positioned ~10 mm from the orifice. Nitrogen was used as curtain gas and a potential of -800 V applied to the needle. A Tof MS scan was acquired (m / z 50-2000, 1 s) and accumulated for ~1 min into a single file. Precursor masses determined from Tof MS scans were selected by Q1 for MS-MS analysis. Nitrogen was used as collision gas and a collision energy chosen that reduced the intensity of the precursor ion by ~95%. Tandem mass spectra were accumulated into a single file for ~2 min (m/z 50-1250).
K i n e t i c m e a s u r e m e n t s -Kinetic determinations for the reactions of probucol and DTBP with HOCl were performed with an
Applied Photophysics SX-17 MV stopped-flow spectrophotometer (36) . Typically, 250 timedependent spectra (logarithmic time-base, integration 2.56 ms, dead-time ~2 ms and λ = 350-750 nm, resolution 1 nm) were collected over 100 s at 25 °C. Kinetic data were processed using Pro-Kineticist global analysis software (Pro-Kineticist, Version 4.1; Applied Photophysics: Leatherhead, U.K., 1996) (37). Apparent rate constants (k ) were then determined by linear regression. For these experiments probucol and DTBP were dissolved in 70% aqueous ethanol to enhance mixing with HOCl, as no meaningful kinetic data were obtained using the hexane/aqueous HOCl conditions described above.
Electronic spectroscopy-Electronic spectra were measured with a Hitachi UV/Vis spectrophotometer.
Spectra of authentic compounds and analytically pure oxidation products were obtained in ethanol (purity 99.7%) and maxima determined by manual peak picking.
Statistical analyses-Statistical analyses were performed using the Prism statistical program (GraphPad, San Diego, CA). Concentrationresponse curves were compared by two-way ANOVA. Student t-tests were performed to determine significant changes between paired data sets with Welch's correction employed for unequal variances where appropriate. In all cases, statistical significance was accepted at the 95% confidence interval (P < 0.05).
RESULTS
It was reported recently that pre-treatment of aortic rings with non-cytotoxic concentrations of reagent HOCl (0-500 µM) resulted in a dosedependent loss of endothelium-dependent relaxation (16) . Consistent with this, treating aortic rings from control rabbits with 400 µM HOCl essentially abolished subsequent relaxation in response to acetylcholine (Fig. 1A) . In contrast, rings from probucol-supplemented animals treated with HOCl retained responsiveness to acetylcholine, as judged by their relaxation (Fig. 1A ) and greater content of cGMP (Fig. 1B) , although the extent of relaxation did not reach that of the native vessel without oxidant treatment (Fig. 1A) . Aortas from probucol-fed rabbits contained probucol at 100 pmol/mg protein (Fig. 1C) , demonstrating the presence of the drug in this tissue. Similar to the situation with in vivo supplemented probucol, pre-incubation of aortic rings from control animals with increasing amounts of added probucol for 10 min followed by thorough washing also protected the vessels from HOClinduced loss of response to acetylcholine in a concentration dependent manner, with full protection seen with 100 µM of the drug (Fig.  2) . Rings pre-treated with 100 µM probucol responded to acetylcholine by increased tissue content of cGMP (Fig. 2B) , and contained ~400 pmol drug/mg protein (Fig. 2C) .
As a phenol, probucol is known to scavenge 1-electron (1e ), i.e., radical oxidants (see e.g., ref. (38) , while little is known about its ability to scavenge 2-electron (2e) oxidants such as HOCl. Therefore, we examined the oxidation of probucol by HOCl. Reaction with HOCl resulted in the dose-dependent consumption of probucol as judged by HPLC (Fig. 3A) . This consumption occurred within minutes (data not shown), and resulted in the appearance of several oxidation products (compounds labelled 1-7 in Fig. 3B ). Others (39) reported oxidation of probucol to DPQ that co-eluted with 7 and appeared as a negative peak at 270 nm (Fig. 3B , solid line) and as a positive peak at 420 nm (Fig.  3B, dashed line) (33) . Based on this, we assigned 7 as DPQ. Similarly, structural assignment for 3 was verified by spiking with authentic DTBP (not shown), mass (Table 1) and 1 H-NMR analyses of an analytically pure sample that showed singlet absorptions at 5.27, 7.33 and 1.40 ppm in the ratio 1:2:18, assigned as phenolic, aromatic and methyl H-atoms, respectively. The identities of the remaining oxidation products were assigned by isolating sufficient analytically pure material for use in negative ion ESI-MS (see Fig. I , Supplementary Material for representative mass spectra). Table  1 summarizes the mass determinations of the isolated products 1-6. DTBP, DPQ and all other oxidation products were detected in samples of probucol oxidized with HOCl, independent of the mol ratio of oxidant to target (Fig. 3B ). Structures were assigned to the various products based on experimentally determined molecular weights (Table 1 ) and known chemistry of sulfur-containing molecules (40) . Oxidation product 1, assigned as a chlorophenol, showed the expected isotopic distribution for chlorine in the corresponding parent ion detected by mass spectrometry (Fig. I, Supplementary Material) . Using these assignments, the concentration of DTBP and 'combined products' (defined as DPQ plus 2 , 4 and 6 ) were quantified retrospectively using corresponding authentic standards prepared from the isolated products. With HOCl at ≤2-mol oxidant per probucol, consumption of probucol was matched by a near stoichiometric accumulation of DTBP (filled circles) plus the combined products (open triangles) (Fig. 3A) . Thereafter, the combined products increased slightly while DTBP decreased and was almost depleted with 5-mol HOCl per mol probucol.
As oxidation of probucol with HOCl consistently generated DTBP as a major intermediate over the oxidant concentrations tested (not shown), we next examined HOClinduced oxidation of DTBP. HOCl dosedependently oxidized DTBP resulting in a near stoichiometric accumulation of the combined products ( Fig. 3C ) with a pattern (Fig. 3D ) similar to that for probucol. Notably, the aqueous phase of reaction mixtures containing probucol or DTBP oxidized with 5-mol equivalent HOCl also contained SO 4 2-at final concentrations of 139 ± 14 or 204 ± 43 nmol, respectively. By comparison, the concentration of SO 4 2-in the antioxidant-free mixtures containing hexane, water and HOCl was significantly lower (58 ± 5 nmol) indicating that HOCl-mediated oxidation of probucol and DTBP produced SO To determine whether the probucol oxidation profile identified was specific to reactions with HOCl, additional 2e-and 1e-oxidants were tested ( Oxidation of probucol and DTBP by HOCl was then analyzed by rapid scan absorbance spectrometry (Fig. 4) . Oxidation resulted in the time-dependent increase in absorption at 440 nm, reflecting accumulation of DPQ (λ max = 440 nm (29)) (Fig. 4 A) . This optical change was used to determine the observed rate constants (k obs ) (Fig. 4B) . Kinetic analyses indicated that probucol was oxidized in a biphasic process with the best fit to the data obtained using a simplified 3 species approach (a→b→c) to yield a low residual (Fig. 4B and  inset) . In contrast to probucol, DTBP was oxidized directly to DPQ (a→ b) (data not shown). Plots of the observed rate constants versus HOCl concentration gave corresponding rate constants (Fig. 4C) . Thus, probucol oxidized with rate constants k 1 and k 2 of 2.7 ± 0.3 x 10 2 and 0.7 ± 0.2 x 10 2 M -1 s -1 , respectively, corresponding to the rapid and slow phase of DPQ accumulation. In contrast, DTBP was oxidized in a single rate-determining process with k = 0.7 ± 0.1 x 10 2 M -1 s -1 . As in vivo and in vitro added probucol protected aortic rings from HOCl-induced endothelial dysfunction, and HOCl converted probucol to DTBP that itself can scavenge HOCl, we next examined whether DTBP attenuated HOCl-induced endothelial dysfunction. Indeed, dietary DTBP preserved the vascular function of isolated rings (Fig. 1A) to an extent comparable to that seen with probucol. In contrast, rings from rabbits supplemented with BP that unlike probucol and DTBP lacks the sulfur atoms, responded to HOCl indistinguishably from control (Fig. 1A) . As with probucol, the protection seen with dietary DTBP was associated with an increase in tissue cGMP, whereas supplementation with BP was ineffective (Fig. 1B) , although all three phenols accumulated to a comparable extent (Fig. 1C) . DTBP also protected aortic rings from HOCl-induced dysfunction when added in vitro (Fig. 2) , to an extent comparable to that seen with the identical concentrations of probucol.
Finally, we assessed tissue samples from the vascular reactivity studies for their contents of probucol and DTBP as well as their respective oxidation products (Fig. 5) . Rings from probucol-supplemented animals contained probucol, BP and DPQ, and treatment with HOCl tended to decrease tissue probucol and BP, and to increase DPQ (Fig. 5A ), although this did not reach statistical significance; products other than BP and DPQ were not detected (not shown). In aortic rings to which probucol was added in vitro, subsequent treatment with HOCl significantly decreased tissue probucol without substantial accumulation of DPQ; BP was not detected (Fig. 5B) . Results comparable to those with probucol were obtained with rings from animals supplemented with DTBP ( Fig. 5C ) and rings to which DTBP was added in vitro prior to HOCl exposure (Fig. 5D ).
DISCUSSION
Vascular endothelial cells overlying atherosclerotic lesions contain myeloperoxidase and proteins modified by its principle product HOCl (13, 41) , and blood vessels exposed to HOCl exhibit a defect in endothelium-derived • NO bioactivity manifested as impaired endothelium-dependent arterial relaxation (16 • NO availability and damages endothelial nitric oxide s y n t h a s e directly (5) or indirectly (49) . Similarly, HOCl effectively decreases L-arginine availability (15) and enhances superoxide anion radical production via endothelial nitric oxide synthase uncoupling (16) . Therefore, the ability of probucol and DTBP to attenuate HOClinduced endothelial dysfunction may result from decreased vascular superoxide anion radical production, as suggested previously for probucol (27) , or from oxidant scavenging.
This study shows for the first time that probucol and DTBP scavenge HOCl and that DTBP is an intermediate during HOCl-mediated oxidation of probucol. Probucol and DTBP also react with other oxidants. Using Cu 2+ -ions, a previous study identified BP and DPQ as oxidation products of probucol, with a spiroquinone proposed as intermediate (39) . We failed to detect the spiroquinone, independent of whether Cu 2+ , HOCl or other oxidants were employed, including lead dioxide used in ref. 39 to produce spiroquinone standard, and whether the HPLC conditions described here or in ref. 39 were used for detection of products. Notwithstanding this, DTBP was detected consistently and to an extent proportional to the yield of DPQ, independent of whether 2e-or 1e-oxidants were used (not shown). Overall, our data from the product precursor studies, together with structural assignments of the various products suggest that oxidation of the sulfur atoms to the disulfoxide 5 is the first step in HOCl-mediated conversion of probucol to DTBP 3 (Scheme 1). This is distinct from the oxidation of probucol's phenolic group.
T he precise mechanism for the rearrangement of 5 to 3 remains to be elucidated. One chemically feasible pathway is via a nonradical mechanism (see Scheme I, Supplementary Material), although in the present study we did not seek direct evidence for the intermediates proposed in this pathway. In this scheme, DTBP is formed via disproportionation of two molecules of thiosulfinate, or via coupling of the thiophenol and phenylsulfonic acid. Coupling of thiophenol radicals to DTBP is an alternative pathway (not shown in Scheme I), supported by the detection of phenoxyl radicals during the electrochemical oxidation of probucol (50) , although in that publication no explanation was given for the loss of the propyl group. In any case, our results suggest that DTBP is further oxidized by HOCl to yield the thiosulfonate 4 that oxidizes to the disulfone 6, which becomes hydrolysed to the corresponding sulfonic acid 2. The acid product 2 is then chlorinated by another molecule of HOCl to yield the chlorophenol 1 and 2H + /SO 4 2-as byproduct that we detected in HOCl-mediated oxidations of probucol and DTBP. Finally, the chlorophenol intermediate is converted to DPQ. Again the precise mechanism for this is not clear with oxidation of 1 to the chloroquinone cation that then couples to displace molecular Cl 2 to yield DPQ being one possibility (see Scheme II, Supplementary Material). Irrespective of the precise mechanism of its formation, DPQ is degraded in the presence of excess HOCl.
As our in vitro studies clearly establish that probucol and DTBP can scavenge HOCl, and the two phenols protect vessels from HOClinduced endothelial dysfunction, it is tempting to speculate that the latter activity of probucol and DTBP is due to HOCl scavenging. In support of such a notion, unlike probucol and DTPB, BP failed to protect (Fig. 1) . This indicates that radical scavenging by the phenolic moiety alone cannot be responsible for the protection seen with probucol and DTBP, a conclusion also in line with the observation that vitamin E, another phenolic antioxidant, fails to protect against HOCl-mediated endothelial dysfunction (16) . Rather, comparing the efficacy of probucol, DTBP and BP points to the importance of the sulfur atoms for protection against HOClmediated endothelial dysfunction.
Close examinations of the data indicate that the observed inhibition of HOCl-mediated endothelial dysfunction by probucol and DTBP is not likely due to direct scavenging of HOCl. First, the rate constants for the reaction of HOCl with probucol and DTBP are orders of magnitude lower than those for reaction of HOCl with several biological targets, such as heme (51) , ascorbate (52) and amino acids (37) . Based on kinetic arguments therefore, direct reaction of HOCl with probucol or DTBP present in the vessel wall is not favored. Consistent with this argument, probucol is inefficient in preventing carbonyl formation on albumin exposed to HOCl (53), and probucol-or DTBP-containing vessels exposed to HOCl did not contain measurable oxidation products despite a clear consumption of the respective phenolic compounds (Fig. 5) . Also, we observed that equimolar amounts cysteine or reduced glutathione completely protected probucol and DTBP from HOCl-induced oxidation (not shown). Second, HOCl-mediated endothelial dysfunction is inhibited by superoxide dismutase (16) indicating the involvement of superoxide anion radical, perhaps via destabilizing endothelial nitric oxide synthase dimer. Therefore, the protection afforded by probucol and DTBP to vessels against HOCl-induced endothelial dysfunction appears more complex, and we cannot rule out protection via presently unknown chemistry or novel pharmacologic actions of the drugs.
In summary, we have established a novel role for probucol in protecting aortic vessels against the deleterious effects of the potent 2e-oxidant HOCl. In doing so, we have identified, for the first time, the likely importance of the sulfur atoms in this protective activity. In this context, conversion of probucol into DTBP could be pharmacologically important. Indeed, the observed comparable protective activity of probucol and DTBP (Figs. 1 and 2) suggests that probucol is a pro-drug, with DTBP the active component. Thus, if probucol were the active component and becomes oxidized during its action, one would have expected it to be more active than equimolar concentrations of DTBP alone. Further studies will be required to substantiate this possibility, as well as to test whether DTBP can account, at least in part Figure I ). 
